Related Experiment Video
Updated: Jun 1, 2026

A Syngeneic Mouse Model of Metastatic Renal Cell Carcinoma for Quantitative and Longitudinal Assessment of Preclinical Therapies
Published on: April 12, 2017
Recent developments in kidney cancer
Michael J Leveridge1, Michael A S Jewett
1Assistant Professor, Department of Urology, Kingston General Hospital, Queen's University, Kingston, ON;
Abstract:
Renal cell carcinoma (RCC) diagnosis and management have undergone significant shifts in the recent past. The increasing rate of diagnosis of small renal masses, often in patients at high risk of morbidity with operative treatment, has led to studies, trials and discoveries in renal mass biopsy, active surveillance and minimally invasive thermal ablation. At the other end of the disease spectrum, targeted systemic therapies for metastatic RCC have supplanted cytokine-based treatment, with significant benefits to progression and survival. Recent reviews and trials have also cemented the role of partial nephrectomy as standard surgical management for most low-stage masses, and the roles of regional lymphadenectomy and adrenalectomy concomitant with nephrectomy have been clarified. This review aims to highlight recent evidence that has emerged in the management of this complicated oncologic issue.
Related Concept Videos
Kidney Transplant I: Introduction
Acute Kidney Injury IV: Diagnostic Studies and Prevention
Kidney Transplant III: Nursing Management
Kidney Transplant II: Surgical Procedure
Chronic Kidney Disease III: Interprofessional Care
Chronic Kidney Disease I: Introduction

